Corcept Therapeutics Inc
Change company Symbol lookup
Select an option...
CORT Corcept Therapeutics Inc
CVS CVS Health Corp
NVAX Novavax Inc
MRK Merck & Co Inc
HYT BlackRock Corporate High Yield Fund, Inc
FNMA Federal National Mortgage Association
CPKF Chesapeake Financial Shares Inc
AGNC Agnc Investment Corp
BYND Beyond Meat Inc
NDENF Central African Gold Inc

Health Care : Pharmaceuticals | Small Cap Growth
Company profile

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). As of December 31, 2016, it had discovered three structurally distinct series of selective cortisol modulators, all of which share mifepristone's affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor. It is conducting two clinical trials of its selective cortisol modulator, CORT125134. One trial is investigating CORT125134 as a treatment for patients with Cushing syndrome. The second trial is investigating the combination of CORT125134 and nab-paclitaxel (Celgene Corporation's Abraxane) to treat patients with solid-tumor cancers.

Closing Price
Day's Change
-0.30 (-1.67%)
B/A Size
Day's High
Day's Low

10-day average volume:

Nasdaq Composite stands less than 1% from exiting correction territory Monday afternoon

2:54 pm ET October 12, 2020 (MarketWatch)

The Nasdaq Composite Index on Monday afternoon was surging more than 3% higher, putting the technology-laden index within striking distance of exiting a plunge into correction territory produced back on Sept. 8. A drop of at least 10% for an asset from a recent peak is the commonly used definition on Wall Street for a correction, while putting in a new high after that decline is often viewed as that asset exiting that bearish phase of trading. The Nasdaq Composite sank into correction--after putting in its most recent record high on Sept. 2--early last month but is now nearing a new record peak above 12,056.44, putting the benchmark about 0.8% from its all-time high, according to FactSet data. The Nasdaq has been powered higher by a handful of stocks in its resurgence from its March lows and Monday's trade was no different, with Facebook Inc. (FB) Apple Inc. (AAPL), [: AMZN], Netflix (NFLX) and Google parent Alphabet Inc. (GOOGL)(GOOGL) all rising sharply on the day. The contingent of stocks, known informally as FAANG (and sometimes including Microsoft Cor. (MSFT), has helped to lift the broader market by dint of the market value those handful of those companies. The Nasdaq Composite was recently trading up 3.2% at 11,955, coming after brisk run-up for the index on Friday. The broader market also was gaining altitude briskly, with the Dow Jones Industrial Average [: DJIA] rising 1.1% and the S&P 500 index climbing 2% to 3,547. The S&P 500 had threatened to fall into correction, with a drop to 3,222.76 from its recent September peak, but managed to avoid a close at that level.

-Mark DeCambre; 415-439-6400;

(END) Dow Jones Newswires

October 12, 2020 14:54 ET (18:54 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.